Roivant Sciences Ltd.

Stories

FDA approves Lisraya, first targeted therapy for dermatomyositis

As of September 2026: Parent company of Priovant; trades on Nasdaq as ROIV

The FDA approved Lisraya on August 27, 2026, clearing the first targeted therapy ever approved for dermatomyositis, a rare autoimmune disease that inflames skin and weakens muscles. The once-daily pill is now on sale in the US.

Updated Sep 16

Moderna's battle over the delivery technology in its COVID vaccine

Rule Changes

As of May 2026: Parent of Genevant; announced $1B share buyback

For four years, Moderna faced questions about whether it owed billions for technology at the heart of its COVID-19 vaccine. Less than a week before a jury trial in Delaware, Moderna agreed to pay $2.25 billion to settle patent claims from Arbutus Biopharma and Genevant Sciences. The court found it infringed four valid patents, and if paid in full, it would be the largest disclosed patent settlement in pharmaceutical history, surpassing a $2.15 billion Pfizer-Takeda settlement in 2013.

Updated May 30